Resveratrol suppresses human glioblastoma cell migration and invasion via activation of RhoA/ROCK signaling pathway

WEI XIONG1,2, ANAN YIN1, XINGGANG MAO1, WEI ZHANG1, HUIYONG HUANG1 and XIANG ZHANG1

1Department of Neurosurgery, Xijing Institute of Clinical Neuroscience, Fourth Military Medical University, Xi'an, Shaanxi 710032; 2Trauma Centre, The 196th Hospital of PLA, Zhanjiang, Guangdong 524000, P.R. China

Received November 1, 2014; Accepted September 17, 2015

DOI: 10.3892/ol.2015.3888

Abstract. Numerous studies have demonstrated that resveratrol has a potential use in cancer prevention and treatment. However, the effects of resveratrol on cancer cell motility and invasiveness remain unclear. The current study aimed to examine the effects of resveratrol on cell migration and invasion in human glioblastoma cells, and to explore the underlying molecular mechanisms. In wound-healing and Matrigel transwell assays, resveratrol was found to significantly inhibit the migration and invasion of U87MG, T98G and U251 glioblastoma cells in vitro. Results from western blot analysis and gelatin zymography revealed that resveratrol also suppressed the expression and activity of matrix metalloproteinase 2 (MMP-2; P<0.05), an important mediator of cell migration and invasion. Furthermore, using a pull-down assay, increased activation of RhoA was observed in glioblastoma cells treated with resveratrol vs. controls (P<0.05). Notably, inhibition of the RhoA/Rho-associated kinase (ROCK) pathway by C3 transferase or Y-27362 was found to attenuate the resveratrol-induced reductions in cell migration and invasion (P<0.05), and also partially rescued the decreased expression and activity of MMP-2 induced by resveratrol (P<0.05). Taken together, the results suggest that resveratrol may inhibit glioblastoma cell motility and invasiveness via activating the RhoA/ROCK signaling pathway.

Introduction

Glioblastoma is the most common and lethal intracranial malignant tumor with a yearly incidence of 3-4 per 100,000 (1). Despite the use of multimodal treatments, the prognosis of glioblastoma has been little improved, with a typical median survival time of only 12-15 months (2). Due to the diffuse infiltration of glioblastoma cells into the brain tissues, resection of the bulk tumor is typically followed by tumor reinitiation at the resection site or at another location in the brain. The highly aggressive and invasive properties of glioblastoma cells contribute significantly to the poor prognosis of cases involving this type of tumor (3). Therefore, it has been proposed that anti-invasion agents may play a crucial role in the treatment of glioblastoma (4).

The invasion of malignant cancer cells is favored by degradation of the extracellular matrix (ECM), upregulation of proteolytic enzyme activity and an increase in tumor cell motility and invasive ability (5,6). Accumulating evidence has suggested that matrix metalloproteinases (MMPs) are capable of promoting tumor invasion and metastasis via degradation of the ECM (7), among which two gelatinases, MMP-2 and MMP-9, have attracted the most attention (8). Rho GTPases are a family of small GTP-binding proteins that serve as molecular switches in a wide variety of cellular signaling pathways, ultimately inducing changes in the organization of the actin cytoskeleton and regulating cell motility (9). It has been reported that RhoA activity is significantly reduced in astrocytic tumors (10-12), and increased RhoA activity in glioblastoma cells has been associated with impaired cell migration and invasion through the rearrangement of actin into stress fibers and the induction of focal adhesions (13).

Resveratrol is a natural polyphenol that exists in grapes, berries and peanuts (14). Previous studies reported that resveratrol was able to induce apoptosis and suppress proliferation in various cancer cell types (15,16). In addition, resveratrol has been demonstrated to inhibit cell proliferation and induce apoptosis in glioblastoma cells (17,18). However, the effects of resveratrol on the motility and invasiveness of glioblastoma cells is not well documented. Therefore, the current study aimed to examine the effects of resveratrol on cell migration and invasion in human glioblastoma cells, and to explore the underlying molecular mechanisms.

Materials and methods

Cell culture and chemicals. Human glioblastoma U87MG, T98G and U251 cells were obtained from the cell bank of the Fourth Military Medical University (Xi’an, China) and cultured in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich,
Methyl thiazolyl tetrazolium (MTT) assay. The cytotoxicity of resveratrol was measured using an MTT assay (Sigma-Aldrich). U87MG, T98G and U251 cells were grown in 96-well plates (Greiner Bio-One GmbH, Frickenhausen, Germany) at a density of 5x10⁴ cells/well and cultured for 24 h. Cells were then treated with resveratrol at various concentrations (20-100 µM). Following incubation for 48 h, 20 µl MTT (5 mg/ml) was added to each well and incubated at 37°C for 4 h. Finally, 150 µl DMSO was added to solubilize the formazan crystals, and the amount of formazan salt was determined by measuring the optical density (OD) at 490 nm using a Bio-Rad 680 microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Cell viability was expressed as the percent OD value of each group relative to that of control cells.

Western blot analysis. Western blot analysis was performed as previously described (18). In brief, equivalent amounts (25 µg) of protein lysates were loaded into each well, separated by 8% SDS-PAGE and transferred to nitrocellulose membranes (0.22 µm; EMD Millipore). The membranes were probed with rabbit polyclonal antibodies against human MMP-2 (#B81236; Bio world Technology, Inc., St. Louis Park, MN, USA; dilution, 1:1,000), phosphorylated (p) myosin phosphatase target subunit 1 (MYPT1; #BS4141; Bioworld Technology, Inc.; dilution, 1:1,000) and β-actin (#sc-130656; Santa Cruz Biotechnology, Inc.; dilution, 1:2,000), followed by incubation for 1 h at room temperature with horseradish peroxidase-conjugated goat anti-rabbit IgG secondary antibody (#sc-2004; dilution, 1:5,000; Santa Cruz Biotechnology, Inc.). The membranes were then developed using an ECL system (Cell Signaling Technology, Beverly, MA, USA). The grayscale values of each band on the blots were measured using BandScan software version 4.3 (Glyko Biomedical Ltd., Novato, CA, USA); the integrated density of each band was normalized to the corresponding human β-actin band. Representative results from at least three independent experiments are shown.

Measurement of RhoA activity. RhoA activity was measured using a pull-down assay (Upstate® Rho Activation Assay Kit) according to the manufacturer instructions. Briefly, protein lysates and Rhotekin agarose were incubated for 45 min at 4°C with gentle agitation. Following thorough washes, the samples were boiled for 5 min in Laemmli buffer [60 mM Tris-HCl, pH 6.8; 2% SDS; 10% glycerin (Tianjin Yongda Chemical Reagent Co., Ltd., Tianjin City, China); 5% methanol and stained with hematoxylin and eosin solution. The number of cells in five random fields were counted under a Nikon TS100 light microscope.
β-mercaptoethanol (Sigma–Aldrich); 0.1% bromphenol blue] to detach active GTP-bound Rho and loaded on SDS-PAGE gels and immunoblotted using the anti-RhoA antibody included with the assay kit. The subsequent procedure was performed as for the western blot analysis.

**Statistical analysis.** Data are presented as the mean ± standard deviation of three independent experiments, and were evaluated by one-way analysis of variance using SPSS software version 13.0 (SPSS, Inc., Chicago, IL, USA). *P*<0.05 was considered to indicate statistically significant differences.

Figure 1. Effects of resveratrol on cell viability of glioblastoma. An MTT assay was performed to measure the cell viability of U87MG, T98G and U251 cells treated with increasing concentrations of resveratrol (20-100 µM) for 48 h. Results are representative of three independent experiments (mean ± standard deviation). *P*<0.05 vs. control group (untreated cells).

Figure 2. Resveratrol suppresses human glioblastoma cell migration and invasion *in vitro*. (A) The effect of resveratrol on cell migration was measured by wound healing assay. Photographs were captured and the width of the wound was measured in five random fields following incubation for 48 h (original magnification, x100). Bar graphs represent the mean migration distance relative to the control cells. (B) Matrigel transwell invasion assays were used to measure cell invasiveness. Following incubation with resveratrol for 48 h, cells that invaded through the membrane were stained and representative fields were photographed (original magnification, x200). Bar graphs represent the mean number of invaded cells from five random fields, and all results are representative of three independent experiments (mean ± SD). *P*<0.05 vs. control group (untreated cells).
Results

Resveratrol suppresses human glioblastoma cell migration and invasion in vitro. To rule out a cytotoxic effect on cell number following resveratrol treatment, the viability of U87MG, T98G and U251 cells treated with increasing concentrations of resveratrol (20-100 µM) for 48 h was assessed by MTT assay. Resveratrol inhibited the cell viability of glioblastoma cells in a concentration-dependent manner; however, it had only marginal effects on cell viability up to a concentration of 40 µM in all three cell lines (P>0.05; Fig. 1). However, treatment with 60 µM resveratrol demonstrated significant cytotoxic effects on the cell viability of U87MG and U251 cells (P<0.05; Fig. 1). Thus, the non-cytotoxic concentration of 40 µM resveratrol was used in the subsequent experiments. To evaluate the effects of resveratrol on cell migration and invasion, wound-healing and Matrigel transwell assays were performed, revealing that resveratrol significantly inhibited human glioblastoma cell migration and invasion in vitro. Specifically, resveratrol reduced the migration distance of U87MG cells to 33.5±6.5% relative to the control group (Fig. 2A; P<0.001), and decreased the number of U87MG cells invading through the matrigel by ~64% (Fig. 2B; P<0.001) following incubation for 48 h. Similar results were observed in T98G and U251 cells to a lesser degree (Fig. 2).

Resveratrol inhibits activity and expression of MMP-2 in glioblastoma cells. MMPs, particularly MMP-2, are reported to be crucial for cell migration and invasion in numerous types of tumor, including glioblastoma (19). Using western blot analysis, resveratrol was observed to induce a marked reduction
in MMP-2 protein expression in all three glioblastoma cell lines (P<0.001; Fig. 3A). Furthermore, gelatin zymographic analyses were performed to determine the MMP-2 gelatinolytic activity. As indicated by Fig. 3B, the suppression of MMP-2 activity due to resveratrol was confirmed in the three cell lines, with a reduction to 20-40% relative to each control group (P<0.001).

**Resveratrol increases activation of RhoA in glioblastoma cells.** The Rho family GTPase RhoA has been implicated in the regulation of cell contraction and retraction forces that are required for cell migration and invasion (20). In the current study, the activity of RhoA in glioblastoma cells in response to resveratrol was examined using a pull-down assay. The results revealed that resveratrol significantly increased activity of RhoA in glioblastoma cells (P<0.001; Fig. 4A). Despite the variations of basal RhoA activity among the different glioblastoma cell lines, the increases in RhoA activity induced by resveratrol were 2- to 3-fold higher than the baselines. Furthermore, to confirm the activation of RhoA/Rho-associated kinase (ROCK) signaling by resveratrol, the phosphorylation of MYPT1, a downstream target of ROCK, was examined. The results revealed that resveratrol significantly induced MYPT1 phosphorylation in glioblastoma cells (P<0.001; Fig. 4B).

**Blockade of the RhoA/ROCK pathway reverses the inhibition of migration and invasion in glioblastoma cells induced by resveratrol.** As U87MG cells manifested more sensitive responses to resveratrol treatment, they were selected for use in the subsequent experiments. Wound-healing and Matrigel transwell assays were performed using U87MG cells in the presence of resveratrol alone or in combination with a specific cell-permeable RhoA inhibitor (C3 transferase; 0.25 µg/ml), or ROCK inhibitor (Y-27362; 5 µg/ml). Consistently with our previous data, resveratrol led to significant reductions in the rates of cell migration and invasion relative to that of untreated controls; cell migration was reduced to ~30% (P<0.001), whilst the number of matrigel-invaded cells was decreased to ~40% (P<0.001). By contrast, inhibition of either RhoA or ROCK attenuated the resveratrol-induced reductions in cell migration and invasion, partially restoring the rates of migration and invasion to that of untreated cells (Fig. 5A and B). Next, the ability of inhibition of RhoA/ROCK signaling to interfere with MMP-2 expression and activity was investigated. As expected, western blot and zymographic analyses revealed that blocking RhoA/ROCK signaling partially rescued the decreased expression and activity of MMP-2 induced by resveratrol (P<0.001; Fig. 5C and D).
Discussion

The highly diffuse infiltration of tumor cells typically prevents a successful local treatment for glioblastoma (21). The present study demonstrated the ability of resveratrol to reduce cell migration and invasion in human glioblastoma cells in vitro. Furthermore, the results indicated that activation of RhoA and inhibition of MMP-2 activity may be responsible for the inhibitory effects of resveratrol on cell migration and invasion in glioblastoma cell lines. Thus, this natural dietary compound may be a promising therapeutic agent for the treatment of glioblastoma. Resveratrol is a natural polyphenol that is synthesized by a wide range of plant species. Over the past decades, numerous studies have reported that resveratrol inhibits cell proliferation, induces apoptosis in various kinds of cancer cells in vitro, and retards the growth of implanted tumors in vivo (15,16,22-24). More recent evidence has indicated that resveratrol is able to sensitize cancers to chemotherapy with cisplatin and other conventional anticancer therapeutics (25).

Our previous studies had demonstrated that resveratrol was able to inhibit cell proliferation in U87MG and T98G cells, and could also reverse temozolomide resistance by downregulation of O-6-methylguanine-DNA methyltransferase in T98G glioblastoma cells (18,26,27). The present study further indicated that resveratrol is able to inhibit cell migration and invasion in U87MG, U251 and T98G glioblastoma cells via activation of the RhoA/ROCK pathway.

Tumor cells achieve their invasive ability through the secretion and activation of proteolytic enzymes, including serine, metallo- and cysteine proteases, which can degrade ECM components and break down other natural barriers to tumor invasion (5,6). A number of reports have revealed that elevated expression of MMPs is closely associated with the invasion and aggressiveness of tumor cells, including glioblastoma (8,28,29). Certain MMPs have become promising therapeutic targets for the development of anticancer drugs (30,31). The current results indicated that resveratrol repressed the expression and secretion of MMP-2 in glioblastoma cells, and that cell invasive ability was markedly impaired following MMP-2 gene silencing (data not shown). In accordance with these results, Gagliano et al (32) demonstrated that resveratrol is able to decrease the expression of MMP-2 in primary cultured glioblastoma cells. Notably, MMP-2 is not the only tumor invasion mediator targeted by resveratrol. In our previous study, resveratrol repressed YKL-40 expression and inhibited U87MG cell invasion (26). Another study also demonstrated that resveratrol reduced U373MG human glioma cell invasion through decreasing plasminogen activator and its specific receptor expression (33); urokinase plasminogen activator (uPA) and the uPA receptor are important mediators of cell migration and invasion in various cell types (34).

Rho GTPases, which serve as binary switches that cycle between an active GTP-bound form and an inactive GDP-bound form, are a class of key regulators of the actin cytoskeleton (9). Rho GTPases also coordinate the regulation of other cellular activities, including gene transcription, cell morphological changes and migration (35). RhoA, a well-known member of the Rho protein family, has been reported to be significantly underexpressed in astrocytoma and inversely correlated with tumor malignancy (10). The increase of RhoA activity in glioblastoma cells is reportedly linked with impaired cell migration and invasion through the rearrangement of actin into stress fibers and the induction of focal adhesions (12,36). The role of RhoA is mediated through a major effector, ROCK, activation of which has been shown to inhibit migration and invasion of astrocytoma cells (37). In the current study, based on the observation that resveratrol activated RhoA in glioblastoma cells, and that blockade of the RhoA/ROCK pathway attenuated the resveratrol-induced inhibition of cell migration and invasion, we hypothesize that the inhibitory effect of resveratrol on migration and invasion in glioblastoma cells may be mediated through the RhoA/ROCK pathway. A similar finding was reported in human umbilical vein endothelial cells, in which resveratrol inhibited cell migration through a RhoA/ROCK-dependent mechanism (38). With regard to the effect of the RhoA/ROCK pathway on MMP-2, however, there have been controversial reports. Inhibition of RhoA/ROCK was observed to increase MMP-2 expression and activity in microvascular endothelial cells, whereas MMP-2 activity was decreased in osteosarcoma cells (39,40). The mechanisms underlying the regulation of MMPs by RhoA and the effect on cell migration and invasion require further investigation. Notably, in the present study, the inhibition of cell migration and invasion by resveratrol was only partially restored by blocking the RhoA/ROCK pathway, suggesting the existence of other signaling pathways associated with resveratrol in glioblastoma cells.

In summary, the present findings indicate that resveratrol may inhibit glioblastoma cell motility and invasiveness via downregulation of MMP-2 and activation of the RhoA/ROCK signaling pathway. These findings highlight resveratrol as a promising therapeutic agent for glioblastoma patients, and form a basis for further investigation of this natural dietary compound.

Acknowledgements

The authors would like to thank Miss Juan Li (Xijing Institute of Clinical Neuroscience, Xi’an, China) for her technical assistance. This study was supported by the Chinese National Natural Science Foundation, (grant no. 81471266).

References